Johnson & Johnson (JNJ) Announces Results for Phase 3b APEX Study

Johnson & Johnson (NYSE:JNJ) is one of the 10 Cheapest High-Quality Stocks to Buy According to Hedge Funds. On June 11, Johnson & Johnson (NYSE:JNJ) announced findings from Phase 3b APEX study for TREMFYA, showing that it significantly reduces symptoms for active psoriatic arthritis and also inhibits the progression of joint structural damage.

TREMFYA is currently the only IL-23 inhibitor proven to significantly inhibit the progression of joint structural damage in patients with active PsA. The APEX study showed that the treatment demonstrated a two-and-a-half times greater ability to inhibit joint structural damage compared to placebo after 24 weeks of treatment.

The data showed that over 40% of TREMFYA-treated patients achieved a 50% improvement in joint symptoms, moreover, 67-68% achieved a 20% improvement. The positive results from the study reinforce Johnson & Johnson’s (NYSE:JNJ) TREMFYA as a potential first-in-line treatment option for adults with active psoriatic arthritis.

Johnson & Johnson (NYSE:JNJ) is a healthcare company that researches, develops, manufactures, and sells a wide range of healthcare products. It operates mainly through two segments including Innovative Medicine and MedTech.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.